Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck AstraZeneca by Year
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent receivables from partner ($M) ($M)
Merck AstraZeneca: $125M in FY2025.
Latest, FY2025
125
Period ended Dec 31, 2025
Change on a year earlier
–
0 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent receivables from partner ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 125 | – | Form 10-Q (filed 2026-08-07) ↗ |
| FY2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
Cite this data
StockData. (2026). Merck AstraZeneca ($M), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-astrazeneca-ar-nc
See every metric in the Merck KPI table. Data updated Oct 26, 2026.